Your browser doesn't support javascript.
loading
Pachymeningeal disease: a systematic review and metanalysis.
Gutiérrez-Valencia, Enrique; Sánchez, Irving; Valles, Adrián; Díaz, Omar; F González, Tomás; Balderrama, Ricardo; Fuentes, Jesús; Ruiz, Victor; Rodríguez, José; Saavedra, Carlos; Velázquez-Pulido, Lorena; Cadavid, Eduard; E Ayala-Hernández, Luis; Villalvazo, Alejandro; H Bayardo, Luis; Jamora, Kurl; Kalyvas, Aristotelis; Yang, Kaiyun; Millar, Barbara-Ann; B Shultz, David.
Afiliação
  • Gutiérrez-Valencia E; MHA Radiation Medicine Program, Princess Margaret Cancer Center, University of Toronto, 7th Floor, OPG Building, 700 University Ave., Toronto, ON, M5G2M9, Canada. Enrique.Gutierrez@rmp.uhn.ca.
  • Sánchez I; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • Valles A; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • Díaz O; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • F González T; Department of Radiation Oncology, Cancer Center ABC, The American British Cowdray Medical Center, Mexico City, Las Americas, 01120, Mexico.
  • Balderrama R; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • Fuentes J; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • Ruiz V; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • Rodríguez J; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • Saavedra C; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • Velázquez-Pulido L; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • Cadavid E; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • E Ayala-Hernández L; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • Villalvazo A; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • H Bayardo L; Department of Radiation Oncology, Western National Medical Center, University of Guadalajara, Jalisco, Mexico.
  • Jamora K; MHA Radiation Medicine Program, Princess Margaret Cancer Center, University of Toronto, 7th Floor, OPG Building, 700 University Ave., Toronto, ON, M5G2M9, Canada.
  • Kalyvas A; Division of Neurosurgery, Toronto Western Hospital - University of Toronto, Toronto, ON, Canada.
  • Yang K; Division of Neurosurgery, Toronto Western Hospital - University of Toronto, Toronto, ON, Canada.
  • Millar BA; MHA Radiation Medicine Program, Princess Margaret Cancer Center, University of Toronto, 7th Floor, OPG Building, 700 University Ave., Toronto, ON, M5G2M9, Canada.
  • B Shultz D; MHA Radiation Medicine Program, Princess Margaret Cancer Center, University of Toronto, 7th Floor, OPG Building, 700 University Ave., Toronto, ON, M5G2M9, Canada.
J Neurooncol ; 165(1): 29-39, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37815737
ABSTRACT

BACKGROUND:

Pachymeningeal disease (PMD) is a newly recognized pattern of brain metastasis (BrM) failure that specifically occurs following surgery with adjuvant stereotactic radiosurgery (SRS) and has unique prognostic implications relative to leptomeningeal disease (LMD). Here, we report its prevalence, prognostic implications, and associated risk factors.

METHODS:

A literature search was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses on PUBMED and Cochrane from January 2000 to June 2023.

RESULTS:

We identified 12 studies that included a total of 3992 BrM patients, 659 (16.5%) of whom developed meningeal disease (MD) following surgery plus adjuvant SRS, including either PMD or LMD. The mean prevalence of MD across studies was 20.9% (7.9-38.0%), with PMD accounting for 54.6% of this prevalence and LMD comprising the remaining 45.4%. Mean of the median overall survivals following diagnosis of PMD and LMD was 10.6 months and 3.7 months p = 0.007, respectively, a significant difference. Only 2 risk factors for PMD were reported in ≥ 2 studies and also identified as statistically significant per our meta-

analysis:

infratentorial location and controlled systemic disease status.

CONCLUSION:

While PMD has a superior prognosis to LMD, it is nevertheless a critical oncologic event associated with significant mortality and remains poorly recognized. PMD is predominantly observed in patients with controlled systemic disease status and infratentorial location. Future treatment strategies should focus on reducing surgical seeding and sterilizing surgical cavities.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos / Tratamento / Radioterapia Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Radiocirurgia / Neoplasias Meníngeas Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: J Neurooncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos / Tratamento / Radioterapia Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Radiocirurgia / Neoplasias Meníngeas Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: J Neurooncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá